POM121L9P

Across TCGA pan-cancer cohorts, POM121L9P Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated POM121L9P data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher POM121L9P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated POM121L9P expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, COAD, and UCEC are the cancer types where POM121L9P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.147	0.525	.006	18	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	9	view →
UCEC	OS	Median	All	1.000	0.661	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

POM121L9P–ESCA (DFS)

Open the ESCA breakdown →